免疫抑制与健康个体接种黄热病疫苗后的长期免疫原性
研究比较35名健康个体与40名免疫抑制患者(自身免疫病或器官移植)在接种黄热病疫苗后的长期免疫原性,所有个体均在免疫抑制开始前接种疫苗。中位21.1年后,免疫抑制组35人(88%)血清阳性(PRNT≥1:10),对照组31人(89%),中和抗体几何平均滴度无组间差异。风湿病病程是中和抗体滴度较低的唯一致险因素。
要点
- 免疫抑制治疗前接种黄热病疫苗者,中位21.1年后仍保持较高血清阳性率。
- 免疫抑制组与健康对照组的中和抗体几何平均滴度无差异。
- 风湿病病程较长与中和抗体滴度较低相关。
核心结论
- 接种黄热病疫苗后开始使用免疫抑制药物不影响中和抗体的长期持久性;可能需要第二剂黄热病疫苗以确保长期免疫。
研究设计与样本
- 研究纳入35名健康个体和40名免疫抑制患者(自身免疫病或器官移植),所有个体均在免疫抑制开始前接种过黄热病疫苗,通过蚀斑减少中和试验(PRNT)检测中和抗体。
主要发现
- 黄热病疫苗接种后中位时间间隔21.1年(四分位距14.4-31.3年),免疫抑制组35人(88%)血清阳性(PRNT≥1:10),对照组31人(89%)。
- 两组中和抗体几何平均滴度无差异。
- 风湿病病程是中和抗体滴度较低的唯一致险因素。
- 9名受试者(12%)中和抗体水平不足,均接种过单剂黄热病疫苗(其中1名受试者黄热病疫苗剂次未知)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The live-attenuated yellow fever vaccine (YFV) is generally contraindicated in immunosuppressed patients. Our aim was to investigate if immunosuppressive therapy impairs the long-term protection against yellow fever virus in patients who had received YFV prior to the start of their immunosuppressive therapy. METHODS: Our study examined 35 healthy individuals and 40 immunosuppressed patients with autoimmune diseases or organ transplants. All individuals had received YFV prior to the onset of their immunosuppression. We analysed the long-term influence of the immunosuppressive therapy on the YFV protective immunity by measuring neutralising antibodies (NA) with the Plaque Reduction Neutralisation Test (PRNT). We assessed risk factors for a negative PRNT result (titre below 1: 10) and their influence on the magnitude of the NA. RESULTS: A median time interval of 21.1 years (interquartile range 14.4-31.3 years) after the YFV in all patients, a total of 35 immunosuppressed patients (88%) were seropositive (PRNT ≥ 1:10) compared to 31 patients (89%) in the control group. The geometric mean titres of NA did not differ between the groups. The duration of an underlying rheumatic disease was the only risk factor found for a lower magnitude of NA. An insufficient level of NA was found in nine subjects (12%) who had received a single dose of YFV (in one subject, the number of YFV doses was unknown). CONCLUSION: The use of an immunosuppressive drug started after the administration of the YFV did not affect long-term persistence of NA. A second dose of YFV may be necessary to secure long-term immunity.
引用
- Burkhard J, Ciurea A, Gabay C, et al. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Vaccine. 2020. PMID: 31911033. doi:10.1016/j.vaccine.2019.12.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。